Folates for reduction of risk of neural tube defects: using oral contraceptives as a source of folate

References

• Kondo A, Kamihira O, Ozawa H. Neural tube defects: prevalence, etiology and prevention. Int J Urol. 2009;16(1):49–57.
   PubMed Web of Science ®Google Scholar
• Padmanabhan R. Etiology, pathogenesis and prevention of neural tube defects. Congenit Anom (Kyoto). 2006;46(2):55–67.
   PubMedGoogle Scholar
• Pitkin RM. Folate and neural tube defects. Am J Clin Nutr. 2007;85(1): 285S–288S.
   PubMed Web of Science ®Google Scholar
• Botto LD, Moore CA, Khoury MJ, Erickson JD. Neural-tube defects. N Engl J Med. 1999;341(20):1509–1519.
   PubMed Web of Science ®Google Scholar
• Blencowe H, Cousens S, Modell B, Lawn J. Folic acid to reduce neonatal mortality from neural tube disorders. Int J Epidemiol. 2010; 39 Suppl 1:i110–i121.
   Google Scholar
• Finan A, Clarke TA, Matthews TG, et al. Strategies for reduction of neonatal mortality. Ir J Med Sci. 1999;168(4):265–267.
   Web of Science ®Google Scholar
• Au KS, Ashley-Koch A, Northrup H. Epidemiologic and genetic aspects of spina bifida and other neural tube defects. Dev Disabil Res Rev. 2010;16(1):6–15.
   PubMed Web of Science ®Google Scholar
• Van Allen MI, Boyle E, Thiessen P, et al. The impact of prenatal diagnosis on neural tube defect (NTD) pregnancy versus birth incidence in British Columbia. J Appl Genet. 2006;47(2):151–158.
   Web of Science ®Google Scholar
• Norem CT, Schoen EJ, Walton DL, et al. Routine ultrasonography compared with maternal serum alpha-fetoprotein for neural tube defect screening. Obstet Gynecol 2005;106(4):747–752.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Recommendations for use of folic acid to reduce number of spina bifida cases and other neural tube defects. JAMA. 1993;269(10):1233, 1236–8. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00019479.htm. Accessed on October 11, 2011.
   Google Scholar
• Johnston RB Jr. Will increasing folic acid in fortified grain products further reduce neural tube defects without causing harm? consideration of the evidence. Pediatr Res. 2008;63(1):2–8.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Spina bifida and anencephaly before and after folic acid mandate – United States, 1995–1996 and 1999–2000. MMWR Morb Mortal Wkly Rep. 2004;53(17):362–365.
   Google Scholar
• Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 1972;107(3):458–461.
   PubMed Web of Science ®Google Scholar
• van der Linden IJ, Afman LA, Heil SG, Blom HJ. Genetic variation in genes of folate metabolism and neural-tube defect risk. Proc Nutr Soc. 2006;65(2):204–215.
   Web of Science ®Google Scholar
• Buccimazza SS, Molteno CD, Dunne TT, Viljoen DL. Prevalence of neural tube defects in Cape Town, South Africa. Teratology. 1994;50(3):194–199.
   Google Scholar
• Chatkupt S, Skurnick JH, Jaggi M, Mitruka K, Koenigsberger MR, Johnson WG. Study of genetics, Epidemiology, and vitamin usage in familial spina bifida in the United States in the 1990s. Neurology. 1994;44(1):65–70.
   Web of Science ®Google Scholar
• Milunsky A, Alpert E, Neff RK, Frigoletto FD Jr. Prenatal diagnosis of neural tube defects. IV Maternal serum alpha-fetoprotein screening. Obstet Gynecol. 1980;55(1):60–66.
   Web of Science ®Google Scholar
• Hall J, Solehdin F Folic acid for the prevention of congenital anomalies. Eur J Pediatr. 1998;157(6):445–450.
   PubMed Web of Science ®Google Scholar
• Becerra JE, Khoury MJ, Cordero JF, Erickson JD. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population- based case-control study. Pediatrics. 1990;85(1):1–9.
   PubMed Web of Science ®Google Scholar
• Lammer EJ, Sever LE, Oakley GP Jr. Teratogen update: valproic acid. Teratology. 1987;35(3):465–473.
   Google Scholar
• Edwards MJ, Shiota K, Smith MS, Walsh DA. Hyperthermia and birth defects. Reprod Toxicol. 1995;9(5):411–425.
   PubMed Web of Science ®Google Scholar
• Graham JM Jr, Edwards MJ, Edwards MJ. Teratogen update: gestational effects of maternal hyperthermia due to febrile illnesses and resultant patterns of defects in humans. Teratology. 1998;58(5):209–221.
   Google Scholar
• Shaw GM, Velie EM, Schaffer D. Risk of neural tube defect-affected pregnancies among obese women. JAMA. 1996;275(14):1093–1096.
   PubMed Web of Science ®Google Scholar
• Watkins ML, Scanlon KS, Mulinare J, Khoury MJ. Is maternal obesity a risk factor for anencephaly and spina bifida? Epidemiology. 1996;7(5):507–512.
   Web of Science ®Google Scholar
• Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. JAMA. 1996;275(14):1089–1092.
   PubMed Web of Science ®Google Scholar
• Brender JD, Felkner M, Suarez L, Canfield MA, Henry JP. Maternal pesticide exposure and neural tube defects in Mexican Americans. Ann Epidemiol. 2010;20(1):16–22.
   Web of Science ®Google Scholar
• Blatter BM, Roeleveld N, Zielhuis GA, Mullaart RA, Gabreels FJ. Spina bifida and parental occupation. Epidemiology. 1996;7(2):188–193.
   Web of Science ®Google Scholar
• Shaw GM, Nelson V, Olshan AF. Paternal occupational group and risk of offspring with neural tube defects. Paediatr Perinat Epidemiol. 2002;16(4):328–333.
   Web of Science ®Google Scholar
• Vrijheid M, Dolk H, Stone D, Abramsky L, Alberman E, Scott JE. Socioeconomic inequalities in risk of congenital anomaly. Arch Dis Child. 2000;82(5):349–352.
   PubMed Web of Science ®Google Scholar
• Wasserman CR, Shaw GM, Selvin S, Gould JB, Syme SL. Socioeconomic status, neighborhood social conditions, and neural tube defects. Am J Public Health. 1998;88(11):1674–1680.
   Web of Science ®Google Scholar
• Prasad PD, Ramamoorthy S, Moe AJ, Smith CH, Leibach FH, Ganapathy V. Selective expression of the high-affinity isoform of the folate receptor (FR-alpha) in the human placental syncytiotrophoblast and choriocarcinoma cells. Biochim Biophys Acta. 1994;1223(1):71–75.
   Web of Science ®Google Scholar
• De Marco P, Moroni A, Merello E, et al. Folate pathway gene alterations in patients with neural tube defects. Am J Med Genet. 2000;95(3):216–223.
   Web of Science ®Google Scholar
• Boyles AL, Hammock P, Speer MC. Candidate gene analysis in human neural tube defects. Am J Med Genet C Semin Med Genet. 2005;135C(1):9–23.
   PubMed Web of Science ®Google Scholar
• Dalal A, Pradhan M, Tiwari D, et al. MTHFR 677C – >T and 1298A – >C polymorphisms: evaluation of maternal genotypic risk and association with level of neural tube defect. Gynecol Obstet Invest. 2007;63(3):146–150.
   Web of Science ®Google Scholar
• Muñoz JB, Lacasaña M, Cavazos RG, Borja-Aburto VH, Galavíz-Hernández C, Garduño CA. Methylenetetrahydrofolate reductase gene polymorphisms and the risk of anencephaly in Mexico. Mol Hum Reprod. 2007;13(6):419–424.
   Web of Science ®Google Scholar
• Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000;151(9):862–877.
   PubMed Web of Science ®Google Scholar
• Harmon DL, Woodside JV, Yarnell JW, et al. The common ‘thermolabile’ variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM. 1996;89(8):571–577.
   Google Scholar
• Kirke PN, Mills JL, Molloy AM, et al. Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. BMJ. 2004;328(7455):1535–1536.
   PubMedGoogle Scholar
• Miyaki K, Murata M, Kikuchi H, et al. Assessment of tailor-made prevention of atherosclerosis with folic acid supplementation: randomized, double-blind, placebo-controlled trials in each MTHFR C677T genotype. J Hum Genet. 2005;50(5):241–248.
   Web of Science ®Google Scholar
• Rasmussen SA, Erickson JD, Reef SE, Ross DS. Teratology: from science to birth defects prevention. Birth Defects Res A Clin Mol Teratol. 2009;85(1):82–92.
   Google Scholar
• De-Regil LM, Fernández-Gaxiola AC, Dowswell T, Peña-Rosas JP Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2010;10: CD007950.
   Google Scholar
• Oakley GP Jr. The scientific basis for eliminating folic acid-preventable spina bifida: a modern miracle from epidemiology. Ann Epidemiol. 2009;19(4):226–230.
   PubMed Web of Science ®Google Scholar
• MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338(8760):131–137.
   PubMed Web of Science ®Google Scholar
• Smithells RW, Nevin NC, Seller MJ, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet. 1983;1(8332):1027–1031.
   Web of Science ®Google Scholar
• Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327(26):1832–1835.
   PubMed Web of Science ®Google Scholar
• Hibbard BM. The role of folic acid in pregnancy; with particular reference to anaemia, abruption and abortion. J Obstet Gynaecol Br Commonw. 1964;71:529–542.
   PubMedGoogle Scholar
• Selhub J, Rosenberg IH. Public health significance of supplementation or fortification of grain products with folic acid. Food Nutr Bull. 2008;29(2 Suppl):S173–S176.
   Web of Science ®Google Scholar
• Hibbard BM, Hibbard ED, Jeffcoate TN. Folic acid and reproduction. Acta Obstet Gynecol Scand. 1965;44(3):375–400.
   Web of Science ®Google Scholar
• Grosse SD, Collins JS. Folic acid supplementation and neural tube defect recurrence prevention. Birth Defects Res A Clin Mol Teratol. 2007;79(11):737–742.
   PubMed Web of Science ®Google Scholar
• Kirke PN, Daly LE, Elwood JH. A randomised trial of low dose folic acid to prevent neural tube defects. The Irish Vitamin Study Group. Arch Dis Child. 1992;67(12):1442–1446.
   Web of Science ®Google Scholar
• Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA. 1988;260(21):3141–3145.
   Web of Science ®Google Scholar
• Bower C, Stanley FJ. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med J Aust. 1989;150(11):613–619.
   Web of Science ®Google Scholar
• Mills JL, Rhoads GG, Simpson JL, et al. The absence of a relation between the periconceptional use of vitamins and neural-tube defects. National Institute of Child Health and Human Development Neural Tube Defects Study Group. N Engl J Med. 1989;321(7):430–435.
   Google Scholar
• Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA. 1993;269(10):1257–1261.
   PubMed Web of Science ®Google Scholar
• Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology. 1995;6(3):219–226.
   PubMed Web of Science ®Google Scholar
• Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. China US Collaborative Project for Neural Tube Defect Prevention. N Engl J Med. 1999;341(20):1485–1490.
   PubMed Web of Science ®Google Scholar
• Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA. 1989;262(20):2847–2852.
   PubMed Web of Science ®Google Scholar
• Heseker HB, Mason JB, Selhub J, Rosenberg IH, Jacques PF. Not all cases of neural-tube defect can be prevented by increasing the intake of folic acid. Br J Nutr. 2009;102(2):173–180.
   PubMed Web of Science ®Google Scholar
• Martínez-Frías ML. The biochemical structure and function of meth- ylenetetrahydrofolate reductase provide the rationale to interpret the epidemiological results on the risk for infants with Down syndrome. Am J Med Genet A. 2008;146A(11):1477–1482.
   Web of Science ®Google Scholar
• Carlson S, Aupperle P. Nutrient requirements and fetal development: recommendations for best outcomes. J Fam Pract. 2007;56(11 Suppl Womens):S1–S6; quiz S7-S8.
   Google Scholar
• Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, pantothenic acid, biotin and choline. Washington, DC: National Academy Press, 1998.
   Google Scholar
• Simpson JL, Bailey LB, Pietrzik K, Shane B, Holzgreve W. Micronutrients and women of reproductive potential: required dietary intake and consequences of dietary deficiency or excess. Part I – Folate, Vitamin B12, Vitamin B6. J Matern Fetal Neonatal Med. 2010;23(12):1323–1343.
   PubMed Web of Science ®Google Scholar
• Tam C, McKenna K, Goh YI, et al. Periconceptional folic acid supplementation: a new indication for therapeutic drug monitoring. Ther Drug Monit. 2009;31(3):319–326.
   Web of Science ®Google Scholar
• Butriss J. Strategies designed to increase awareness about folates and health and to increase folate intake: a review. Trends Food Sci Technol. 2005;16(6–7):246–252.
   Web of Science ®Google Scholar
• Centers for Disease Control. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep. 1992;41(RR-14):1–7.
   Google Scholar
• US Preventive Services Task Force. Folic acid for the prevention of neural tube defects: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(9):626–631.
   Web of Science ®Google Scholar
• Botto LD, Lisi A, Bower C, et al. Trends of selected malformations in relation to folic acid recommendations and fortification: an international assessment. Birth Defects Res A Clin Mol Teratol. 2006;76(10):693–705.
   Google Scholar
• Olney RS, Mulinare J. Trends in neural tube defect prevalence, folic acid fortification, and vitamin supplement use. Semin Perinatol. 2002;26(4):277–285.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Knowledge and use of folic acid by women of childbearing age – United States, 1995 and 1998. MMWR Morb Mortal Wkly Rep. 1999;48(16):325–327.
   Google Scholar
• Chivu CM, Tulchinsky TH, Soares-Weiser K, Braunstein R, Brezis M. A systematic review of interventions to increase awareness, knowledge, and folic acid consumption before and during pregnancy. Am J Health Promot. 2008;22(4):237–245.
   Web of Science ®Google Scholar
• March of Dimes. Improving Prec onception Health: Women’s Knowledge and Use of Folic Acid, March of Dimes Foundation, White Plans, NY; 2007.
   Google Scholar
• McDonnell R, Johnson Z, Doyle A, Sayers G. Determinants of folic acid knowledge and use among antenatal women. J Public Health Med. 1999;(2):145–149.
   Google Scholar
• de la Vega A, et al. A nationwide program for the use of preconceptional folic acid to prevent the development of open neural tube defects. Who is really using folic acid? P R Health Sci J. 2002;21(1):7–9.
   Google Scholar
• Morin VI, Mondor M, Wilson RD. Knowledge on periconceptional use of folic acid in women of British Columbia. Fetal Diagn Ther. 2001;16(2):111–115.
   Web of Science ®Google Scholar
• Auriel E, et al. Attitudes, and practice among women and doctors concerning the use of folic acid. ISRN Obstet Gynecol. 2011;2011: 946041.
   Google Scholar
• European Surveillance of Congenital Anomalies. Special Report: Prevention of Neural Tube Defects by Periconceptional Folic Acid Supplementation in Europe. Updated December 2009, EUROCAT Central Registry, Newtownabbey, Northern Ireland, UK.
   Google Scholar
• Botto LD, Lisi A, Robert-Gnansia E, et al. International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? BMJ. 2005;330(7491): 571.
   Google Scholar
• Busby A, Abramsky L, Dolk H, et al. Preventing neural tube defects in Europe: a missed opportunity. Reprod Toxicol. 2005;20(3):393–402.
   Web of Science ®Google Scholar
• Poretti A, Anheier T, Zimmermann R, Boltshauser E; Swiss Pediatric Surveillance Unit (SPSU). Neural tube defects in Switzerland from 2001 to 2007: are periconceptual folic acid recommendations being followed? Swiss Med Wkly. 2008;138(41–42):608–613.
   Web of Science ®Google Scholar
• de Walle HE, de Jong-van den Berg LT. Growing gap in folic acid intake with respect to level of education in the Netherlands. Community Genet. 2007;10(2):93–96.
   PubMedGoogle Scholar
• Romano PS, Waitzman NJ, Scheffler RM, Pi RD. Folic acid fortification of grain: an economic analysis. Am J Public Health. 1995;85(5):667–676.
   PubMed Web of Science ®Google Scholar
• Varela-Moreiras G, Murphy MM, Scott JM. Cobalamin, folic acid, and homocysteine. NutrRev. 2009;67 Suppl 1:S69–S72.
   Google Scholar
• Rader JI. Folic acid fortification, folate status and plasma homocysteine. J Nutr. 2002;132(8 Suppl):2466S–2470S.
   Web of Science ®Google Scholar
• US Food and Drug Administration. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Federal Register. 1996;61:8781–8797.
   Google Scholar
• Bentley TG, Willett WC, Weinstein MC, Kuntz KM. Population- level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. Am J Public Health. 2006;96(11):2040–2047.
   Web of Science ®Google Scholar
• Dietrich M, Brown CJ, Block G. The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States. J Am Coll Nutr. 2005;24(4):266–274.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Folate status in women of childbearing age – United States, 1999. MMWR Morb Mortal Wkly Rep. 2000;49(42):962–965.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Folate status in women of childbearing age, by race/ethnicity – United States, 1999–2000. MMWR Morb Mortal Wkly Rep. 2002;51(36):808–810.
   PubMedGoogle Scholar
• Pfeiffer CM, Caudill SP, Gunter EW, Osterloh J, Sampson EJ. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999–2000. Am J Clin Nutr. 2005;82(2):442–450.
   PubMed Web of Science ®Google Scholar
• Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340(19):1449–1454.
   PubMed Web of Science ®Google Scholar
• Lawrence JM, Petitti DB, Watkins M, Umekubo MA. Trends in serum folate after food fortification. Lancet. 1999;354(9182):915–916.
   PubMed Web of Science ®Google Scholar
• Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA. 2001;285(23):2981–2986.
   PubMed Web of Science ®Google Scholar
• Williams LJ, Mai CT, Edmonds LD, et al. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology. 2002;66(1):33–39.
   Google Scholar
• Robbins JM, Tilford JM, Bird TM, Cleves MA, Reading JA, Hobbs CA. Hospitalizations of newborns with folate-sensitive birth defects before and after fortification of foods with folic acid. Pediatrics. 2006;118(3):906–915.
   Web of Science ®Google Scholar
• Canfield MA, Collins JS, Botto LD, Williams LJ, Mai CT, Kirby RS, et al. National Birth Defects Prevention Network. Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: findings from a multi-state population- based study. Birth Defects Res A Clin Mol Teratol. 2005;73(10):679–689.
   Google Scholar
• Mathews TJ, Honein MA, Erickson JD. Spina bifida and anenceph- aly prevalence – United States, 1991–2001. MMWR Recomm Rep. 2002;51(RR-13):9–11.
   Google Scholar
• De Wals P, Tairou F, Van Allen MI, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med. 2007;357(2):135–142.
   PubMed Web of Science ®Google Scholar
• Lopez-Camelo JS, Orioli IM, da Graça Dutra M, et al. Reduction of birth prevalence rates of neural tube defects after folic acid fortification in Chile. Am J Med Genet A. 2005;135(2):120–125.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Folate status in women of childbearing age, by race/ethnicity – United States, 1999–2000, 2001–2002, and 2003–2004. MMWR Morb Mortal Wkly Rep. 2007;55(51–52):1377–1380.
   Google Scholar
• Evans MI, Llurba E, Landsberger EJ, O’Brien JE, Harrison HH. Impact of folic acid fortification in the United States: markedly diminished high maternal serum alpha-fetoprotein values. Obstet Gynecol. 2004;103(3):474–479.
   Web of Science ®Google Scholar
• Erickson JD. Folic acid and prevention of spina bifida and anencephaly. 10 years after the US Public Health Service recommendation. MMWR Recomm Rep. 2002;51(RR-13):1–3.
   PubMedGoogle Scholar
• Mills JL, Signore C. Neural tube defect rates before and after food- fortification with folic acid. Birth Defects Res A Clin Mol Teratol. 2004;70(11):844–845.
   PubMed Web of Science ®Google Scholar
• Cena ER, Joy AB, Heneman K, et al. Learner-centered nutrition education improves folate intake and food- related behaviors in nonpregnant, low-income women of childbearing age. J Am Diet Assoc. 2008;108(10):1627–1635.
   Google Scholar
• Mojtabai R. Body mass index and serum folate in childbearing age women. Eur J Epidemiol. 2004;19(11):1029–1036.
   PubMed Web of Science ®Google Scholar
• Caudill MA, Le T, Moonie SA, Esfahani ST, Cogger EA. Folate status in women of childbearing age residing in Southern California after folic acid fortification. J Am Coll Nutr. 2001;20(2 Suppl):129–134.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Use of supplements containing folic acid among women of childbearing age – United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(1):5–8.
   Google Scholar
• Cena ER, Joy AB, Heneman K, et al. Folate intake and food-related behaviors in nonpregnant, low-income women of childbearing age. J Am Diet Assoc. 2008;108(8):1364–1368.
   Google Scholar
• Brent RL, Oakley GP Jr. The Food and Drug Administration must require the addition of more folic acid in “enriched” flour and other grains. Pediatrics. 2005;116(3):753–755.
   Web of Science ®Google Scholar
• Brent RL, Oakley GP Jr. Triumph and/or tragedy: the present Food and Drug Administration program of enriching grains with folic acid. Pediatrics. 2006;117(3):930–932.
   Web of Science ®Google Scholar
• Wilson RD, Johnson JA, Wyatt P, et al. Pre-conceptional vitamin/ folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can. 2007;29(12):1003–1026.
   PubMedGoogle Scholar
• Nguyen P, Tam C, O’Connor DL, Kapur B, Koren G. Steady state folate concentrations achieved with 5 compared with 1.1 mg folic acid supplementation among women of childbearing age. Am J Clin Nutr. 2009;89(3):844–852.
   Web of Science ®Google Scholar
• Rosenthal J, Milla G, Flores A, et al; Cooperative Folic Acid Research Group. Effect of different dosage and administration schedules of folic acid on blood folate levels in a population of Honduran women of reproductive age. Public Health Nutr. 2008;11(8):822–830.
   Web of Science ®Google Scholar
• Winkels RM, Brouwer IA, Clarke R, Katan MB, Verhoef P. Bread cofortified with folic acid and vitamin B-12 improves the folate and vitamin B-12 status of healthy older people: a randomized controlled trial. Am J Clin Nutr. 2008;88(2):348–355.
   Web of Science ®Google Scholar
• Smith AD, Kim YI, Refsum H. Is folic acid good for everyone? Am J Clin Nutr. 2008;87(3):517–533.
   PubMed Web of Science ®Google Scholar
• Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA. 2009;302(19):2119–2126.
   PubMed Web of Science ®Google Scholar
• Cho E, Hunter DJ, Spiegelman D, et al. Intakes of vitamins A, C and E and folate and multivitamins and lung cancer: a pooled analysis of 8 prospective studies. Int J Cancer. 2006;118(4):970–978.
   PubMed Web of Science ®Google Scholar
• Kim YI. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res. 2007;51(3):267–292.
   PubMed Web of Science ®Google Scholar
• Ulrich CM, Potter JD. Folate and cancer – timing is everything. JAMA. 2007;297(21):2408–2409.
   PubMed Web of Science ®Google Scholar
• Lonn E, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567–1577.
   PubMed Web of Science ®Google Scholar
• Zhang SM, Cook NR, Albert CM, Gaziano JM, Buring JE, Manson JE. Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial. JAMA. 2008;300(17):2012–2021.
   PubMed Web of Science ®Google Scholar
• Wald NJ. Folic acid and the prevention of neural-tube defects. N Engl J Med. 2004;350(2):101–103.
   PubMed Web of Science ®Google Scholar
• Norris JA. From Telling to Teaching: a Dialogue Approach to Adult Learning, North Myrtle Beach, SC: Learning by Dialogue, 2003.
   Google Scholar
• Perlow JH. Comparative use and knowledge of preconceptional folic acid among Spanish- and English-speaking patient populations in Phoenix and Yuma, Arizona. Am J Obstet Gynecol. 2001;184(6):1263–1266.
   PubMed Web of Science ®Google Scholar
• Morgan LM, Major JL, Meyer RE, Mullenix A. Multivitamin use among non-pregnant females of childbearing age in the Western North Carolina multivitamin distribution program. N C Med J. 2009;70(5):386–390.
   Google Scholar
• Schwarz EB, Sobota M, Gonzales R, Gerbert B. Computerized counseling for folate knowledge and use: a randomized controlled trial. Am JPrevMed. 2008;35(6):568–571.
   PubMed Web of Science ®Google Scholar
• Bell KN, Oakley GP Jr. Update on prevention of folic acid-preventable spina bifida and anencephaly. Birth Defects Res A Clin Mol Teratol. 2009;85(1):102–107.
   Google Scholar
• Cronin M, Schellschmidt I, Dinger J. Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives. Obstet Gynecol. 2009;114(3):616–622.
   Web of Science ®Google Scholar
• Raven CR. Fortifying oral contraceptives with folic acid. How this concept could benefit women of reproductive age. AWHONN Lifelines. 2004;8:12–13.
   Google Scholar
• Moos MK, Petersen R, Meadows K, Melvin CL, Spitz AM. Pregnant women’s perspectives on intendedness of pregnancy. Womens Health Issues. 1997;7(6):385–392.
   PubMed Web of Science ®Google Scholar
• Nelson AL, Westhoff C, Schnare SM. Real-world patterns of prescription refills for branded hormonal contraceptives: a reflection of contraceptive discontinuation. Obstet Gynecol. 2008;112(4):782–787.
   PubMed Web of Science ®Google Scholar
• Foster DG, Parvataneni R, de Bocanegra HT, Lewis C, Bradsberry M, Darney P. Number of oral contraceptive pill packages dispensed, method continuation, and costs. Obstet Gynecol. 2006;108(5):1107–1114.
   Web of Science ®Google Scholar
• Nelson AL, Pietersz D, Nelson LE, Aguilera L. Documented shortterm continuation rates for combined hormonal contraceptives in an indigent population with ready access to contraceptive supplies. Am J Obstet Gynecol. 2007;196(6):599:e1-e5; discussion 599. e5-e6.
   Web of Science ®Google Scholar
• Ali MM, Cleland J. Oral contraceptive discontinuation and its aftermath in 19 developing countries. Contraception. 2010;81(1):22–29.
   PubMed Web of Science ®Google Scholar
• Pittman ME, Secura GM, Allsworth JE, Homco JB, Madden T, Peipert JF. Understanding prescription adherence: pharmacy claims data from the Contraceptive CHOICE Project. Contraception. 2011;83(4):340–345.
   PubMed Web of Science ®Google Scholar
• Raine TR, Foster-Rosales A, Upadhyay UD, et al. One-year contraceptive continuation and pregnancy in adolescent girls and women initiating hormonal contraceptives. Obstet Gynecol. 2011;117(2 Pt 1):363–371.
   Web of Science ®Google Scholar
• Oakley D, Sereika S, Bogue EL. Oral contraceptive pill use after an initial visit to a family planning clinic. Fam Plann Perspect. 1991;23(4):150–154.
   Google Scholar
• Potter L, Oakley D, de Leon-Wong E, Cañamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect. 1996;28(4):154–158.
   PubMedGoogle Scholar
• Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007;76(4):267–272.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration, Center for Drug Evaluation and Research, Advisory Committee for Reproductive Health Drugs. Summary minutes of the December 15, 2003 meeting. Available at: http://www.fda.gov/ohrms/dockets/ac/03/minutes/4002M1_Final.htm. Accessed June 7, 2010.
   Google Scholar
• Bakker DJ, de Jong-van den Berg LT, Fokkema MR. Controlled study on folate status following folic acid supplementation and discontinuation in women of child-bearing age. Ann Clin Biochem. 2009;46(Pt 3):231–234.
   Google Scholar
• Marr J, Sampson-Landers C, Diefenbach K, Trummer D, Bart S, Blode H. Folate and homocysteine levels after 24 weeks administration of YAZ + levomefolate calcium 0.451 mg. Eur J Contracept Reprod Health Care. 2010;15(S1):159.
   Google Scholar
• Bart S, Marr J, Diefenbach K, Trummer D, Sampson-Landers C. Folate status and homocysteine levels during a 24 week oral administration of a folate-containing oral contraceptive: a randomized, doubleblind, active-controlled, parallel-group, US-based multicenter study. Contraception. 2011. In press.
   Google Scholar
• Food and Drug Administration. Beyaz Highlights of Prescribing Information. 2010. Available at: http://www.accessdata.fda.gov/drug- satfda_docs/label/2010/022532s000lbl.pdf. Accessed April 7, 2011.
   Google Scholar
• Taylor TN, Farkouh RA, Graham JB, et al. Potential Reduction in Neural Tube Defects Associated With Use Of Metafolin-fortified Oral Contraceptives In The United States. AJOG. 2011. In press.
   Web of Science ®Google Scholar
• United States Food and Drug Administration Statistical Review and Evaluation, Clinical Studies: NDA # 22–532/001, Reference ID 2861910. Accessible at: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/UCM2 61694. pdf. Accessed August 13, 2011.
   Google Scholar
• Roth C, Magnus P, Schjoberg S, et al. Folic Acid Supplements in Pregnancy and Severe Language Delay in Children. JAMA. 2011;306(14):1566–1573.
   PubMed Web of Science ®Google Scholar